Chemed Corporation (NYSE: CHE) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 27.58 | EPS (ttm) | 19.92 | Insider Own | 5.36% | Shs Outstand | 13.07M | Perf Week | 1.65% |
| Market Cap | 7.18B | Forward P/E | 19.96 | EPS next Y | 27.53 | Insider Trans | -1.37% | Shs Float | 12.83M | Perf Month | 12.46% |
| Enterprise Value | 7.44B | PEG | 3.83 | EPS next Q | 6.48 | Inst Own | - | Short Float | 4.41% | Perf Quarter | 29.51% |
| Income | 275.00M | P/S | 2.77 | EPS this Y | 28.12% | Inst Trans | - | Short Ratio | 2.50 | Perf Half Y | 22.72% |
| Sales | 2.60B | P/B | 8.64 | EPS next Y | 7.85% | ROA | 17.41% | Short Interest | 566.00K | Perf YTD | 28.43% |
| Book/sh | 63.58 | P/C | 179.55 | EPS next 5Y | 7.20% | ROE | 29.45% | 52W High | 550.64 -1.35% | Perf Year | 26.34% |
| Cash/sh | 3.06 | P/FCF | 22.32 | EPS past 3/5Y | 3.67% -1.11% | ROIC | 19.99% | 52W Low | 361.03 50.46% | Perf 3Y | 6.51% |
| Dividend Est. | 2.80 (0.52%) | EV/EBITDA | 17.25 | Sales past 3/5Y | 5.82% 3.99% | Gross Margin | 30.44% | Volatility | 2.09% 2.46% | Perf 5Y | 15.42% |
| Dividend TTM | 2.40 (0.44%) | EV/Sales | 2.87 | EPS Y/Y TTM | 0.15% | Oper. Margin | 13.46% | ATR (14) | 12.74 | Perf 10Y | 273.44% |
| Dividend Ex-Date | Aug 17, 2026 | Quick Ratio | 0.89 | Sales Y/Y TTM | 6.75% | Profit Margin | 10.60% | RSI (14) | 75.17 | Recom | 2.67 |
| Dividend Gr. 3/5Y | 14.13% 10.76% | Current Ratio | 0.91 | EPS Q/Q | 41.92% | SMA20 | 5.23% | Beta | 0.51 | Target Price | 554.00 |
| Payout | 12.07% | Debt/Eq | 0.16 | Sales Q/Q | 8.72% | SMA50 | 14.68% | Rel Volume | 0.59 | Prev Close | 549.48 |
| Employees | 15,811 | LT Debt/Eq | 0.11 | Earnings | Oct 27 | SMA200 | 25.12% | Avg Volume | 199.33K | Price | 543.21 |
| IPO Date | May 03, 1973 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 8.21% 1.24% | Net Debt/EBITDA | 0.59 | Volume | 118,246 | Change | -1.14% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital | Outperform → Sector Perform | |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold | $550 → $475 |
| Sep-02-25 | Upgrade | Jefferies | Hold → Buy | $550 |
| Nov-05-24 | Reiterated | RBC Capital | Outperform | $697 → $633 |
| May-21-24 | Reiterated | RBC Capital | Outperform | $592 → $697 |
| Apr-28-22 | Reiterated | RBC Capital | Outperform | $592 |
| Mar-11-20 | Upgrade | RBC Capital | Sector Perform → Outperform | |
| Nov-01-19 | Upgrade | JMP Securities | Market Perform → Market Outperform | |
| Jul-19-13 | Downgrade | CL King | Buy → Neutral | |
| Oct-31-12 | Downgrade | CL King | Strong Buy → Buy |
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,595 | 2,530 | 2,431 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,805 | 1,772 | 1,577 | — | — | — | — | — | — | |
| Gross Profit | 790 | 758 | 854 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 441 | 417 | 424 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 64 | — | — | — | — | — | — | |
| Operating Income | 350 | 338 | 366 | — | — | — | — | — | — | |
| Interest Expense | 6 | 2 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 25 | 19 | 35 | — | — | — | — | — | — | |
| Net Income Before Taxes | 369 | 356 | 399 | — | — | — | — | — | — | |
| Income Taxes | 95 | 91 | 97 | — | — | — | — | — | — | |
| Consolidated Net Income | 275 | 265 | 302 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 275 | 265 | 302 | — | — | — | — | — | — | |
| Net Income | 275 | 265 | 302 | — | — | — | — | — | — | |
| EPS (Recurring) | 19.92 | 18.42 | 20.10 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 19.92 | 18.42 | 20.10 | — | — | — | — | — | — | |
| EPS (Diluted) | 19.92 | 18.42 | 19.89 | — | — | — | — | — | — | |
| EBITDA | 431 | 422 | 464 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 27.27 | 23.23 | 26.64 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.72 | 2.37 | 3.27 | — | — | — | — | — | — | |
| Gross Margin | 30.44 | 29.96 | 35.13 | — | — | — | — | — | — | |
| Operating Margin | 13.49 | 13.36 | 15.06 | — | — | — | — | — | — | |
| Net Margin | 10.60 | 10.47 | 12.42 | — | — | — | — | — | — | |
| Shares Outstanding | 13 | 14 | 15 | — | — | — | — | — | — | |
| Market Capitalization | 7,062 | 5,990 | 7,947 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Judkins Brian C | VP and Chief Legal Officer | Aug 10 '26 | Option Exercise | 445.35 | 6,786 | 3,022,145 | 9,222 | Aug 10 |
| Wherley Joel L | CEO - Vitas Healthcare | Aug 05 '26 | Option Exercise | 445.35 | 2,599 | 1,157,465 | 3,451 | Aug 06 |
| MCNAMARA KEVIN J | president and CEO | Aug 03 '26 | Sale | 539.51 | 2,000 | 1,079,020 | 70,418 | Aug 04 |
| MCNAMARA KEVIN J | president and CEO | Aug 03 '26 | Option Exercise | 445.35 | 2,001 | 891,145 | 264,158 | Aug 04 |
| MCNAMARA KEVIN J | president and CEO | Jul 31 '26 | Option Exercise | 445.35 | 2,001 | 891,145 | 92,220 | Aug 04 |
| GRACE PATRICK P | Director | Jul 31 '26 | Sale | 532.00 | 190 | 101,080 | 3,533 | Aug 03 |
| LINDELL ANDREA R | Director | Jun 09 '26 | Sale | 447.33 | 1,347 | 602,554 | 4,578 | Jun 10 |
| WALSH GEORGE J III | Director | May 29 '26 | Sale | 437.83 | 500 | 218,915 | 3,209 | May 29 |
| GRACE PATRICK P | Director | May 08 '26 | Sale | 425.78 | 60 | 25,547 | 3,337 | May 08 |
| MCNAMARA KEVIN J | president and CEO | May 01 '26 | Sale | 421.13 | 2,000 | 842,260 | 90,219 | May 04 |
| MCNAMARA KEVIN J | president and CEO | Mar 27 '26 | Sale | 369.37 | 1,500 | 554,055 | 92,219 | Mar 30 |
| MCNAMARA KEVIN J | president and CEO | Mar 12 '26 | Sale | 403.18 | 2,000 | 806,360 | 93,719 | Mar 13 |
| MCNAMARA KEVIN J | president and CEO | Feb 13 '26 | Option Exercise | 0.00 | 4,374 | 0 | 96,911 | Feb 17 |
| Judkins Brian C | VP and Chief Legal Officer | Feb 13 '26 | Option Exercise | 0.00 | 566 | 0 | 2,538 | Feb 17 |
| Wherley Joel L | CEO - Vitas Healthcare | Feb 13 '26 | Option Exercise | 0.00 | 440 | 0 | 1,290 | Feb 17 |